Two National Nanotech Pioneers to Keynote the Pennsylvania Nanotechnology Conference 2005

Lux Capital's Co-founder a Pioneer in Nanotechnology Investment; Immunicon's

CEO Named Top Leader in Nanotechnology Development

Apr 11, 2005, 01:00 ET from Pittsburgh Life Sciences Greenhouse

    PITTSBURGH, April 11 /PRNewswire/ -- The Pittsburgh Life Sciences
 Greenhouse (PLSG) in conjunction with the Commonwealth of Pennsylvania, today
 announced that two nanotechnology investment and development pioneers will
 keynote The Business of Nano: Pennsylvania Nanotechnology Conference 2005.
 The PLSG, a private/public partnership putting the region's life sciences
 industry on a fast track for growth, said that Josh Wolfe, co-founder of Lux
 Capital, will deliver his remarks Tuesday, April 19 at 8:30 a.m. at the
 Pittsburgh Westin Convention Center Hotel.  Edward Erickson, Chairman, CEO and
 President of Immunicon Corporation will provide the keynote address on
 Wednesday, April 20 at 8:30 a.m.
     Wolfe, the Managing Partner of Lux Capital, focuses his firm's venture
 investments in nanotechnology.  The firm's investment holdings represent a
 diversified portfolio with broad exposure to nanotech assets, including
 Nanosys, Molecular Imprints, Cambrios and Lux Research.  He is the author of a
 column at Forbes magazine and the Editor of Forbes' monthly investment
 publication, the "Forbes/Wolfe Nanotech Report."  Wolfe will give a "state of
 the industry" overview and share his insights about all of the attention
 focused on nanotechnology and its potential to become "the next big thing."
 Mr. Wolfe said," For the past few years I've declared regional domination in
 nanotech to be up for grabs. Pennsylvania is as strong a contender as any
 other I've seen. And there's mounting evidence from the players at this year's
 event that energy and momentum is building". He continues, "You'd be remiss to
 watch from the sidelines when the people of a region want it this bad." Wolfe
 is renowned for his pioneering thought leadership and investment acumen in
     In his keynote presentation, Mr. Erickson will discuss strategies for new
 and established, small and larger-size nanotechnology companies, and will
 examine Immunicon's own progress since its IPO in April 2004. Mr. Erickson
 said, "As we look back on 2004, it was clearly a year of substantial progress
 for Immunicon from both a business and scientific perspective. Among the most
 notable accomplishments were the presentation of our data in metastatic breast
 cancer at the June 2004 American Society of Clinical Oncology's annual meeting
 and publication of these data and related data in the New England Journal of
 Medicine in August 2004. I am honored and excited to be invited to share
 Immunicon's experiences with our peers."
     About the Conference
     The Business of Nano: Pennsylvania Nanotechnology Conference 2005, will be
 held April 18-20 at the Westin Convention Center Hotel in Pittsburgh.  The
 conference will feature programs and workshops ranging from electronics to
 instrumentation, all focused on developing the region's nanotechnology
 resources to spur economic growth.
     Nanotechnology is research and technology development at the atomic,
 molecular and macromolecular levels.  Researchers work to develop new
 technologies in industries such as biopharmaceuticals, therapeutics, advanced
 materials, agriculture, chemicals, electronics, energy, defense and
     About Lux Capital
     Lux Capital is a venture capital firm focused on making early-stage
 investments in nanotechnology and related growth sectors emerging from leading
 academic centers of excellence.
     Lux Capital's managing partners, investors, advisors and extended network
 are leveraged to provide unparalleled access, expertise and market
 intelligence to its portfolio companies. The firm's principals are recognized
 internationally as thought-leaders in the field of nanotechnology. Established
 in 2000, the firm is headquartered in New York.
     About the Forbes/Wolfe Nanotech Report
     The Forbes Wolfe Nanotech Report is the first publication targeting the
 business of nanotechnology, the precision creation and manipulation of atomic
 scale matter. Each monthly issue of the Forbes/Wolfe Nanotech Report brings
 you in depth and expert analysis of what corporate executive, venture
 capitalists, politicians and scientists alike call the "next Industrial
     No other newsletter precisely targets how trends in nanotechnology affect
 Wall Street and the investor community.
     About Immunicon Corporation
     Immunicon Corporation is developing and commercializing proprietary cell-
 based research and human diagnostic products with an initial focus on cancer
 disease management. The company has developed platform technologies for
 selection and analysis of rare cells in blood, such as circulating tumor
 cells. Immunicon's products and underlying technology platforms also have
 application in the clinical development of cancer drugs and in cancer
 research, and may have application in other fields of medicine, such as
 cardiovascular and infectious diseases.

SOURCE Pittsburgh Life Sciences Greenhouse